TY - JOUR
T1 - No advantage for patients who receive splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia
T2 - Results of a prospective randomized study
AU - Gratwohl, A.
AU - Hermans, J.
AU - Biezen v., A.
AU - Arcese, W.
AU - De Witte, T.
AU - Debusscher, L.
AU - Ernst, P.
AU - Ferrant, A.
AU - Frassoni, F.
AU - Gahrton, G.
AU - Iriondo, A.
AU - Kolb, H. J.
AU - Link, H.
AU - Niederwieser, D.
AU - Ruutu, T.
AU - Schmitz, N.
AU - Siegert, W.
AU - Torres-Gomez, A.
AU - Vernant, J. P.
AU - Zwaan, F. E.
PY - 1992
Y1 - 1992
N2 - A total of 239 patients with chronic myeloid leukaemia (CML) in chronic phase awaiting bone marrow transplantation (BMT) from an HLA-identical sibling donor were randomized to receive, as part of their conditioning, splenic irradiation (SI+) or no splenic irradiation (SI-). There was no difference between the SI+ and SI- groups regarding the distribution of age, sex, donor/recipient sex combination and blood counts at diagnosis and at BMT. Survival, leukaemia-free survival (LFS), incidence of transplant-related mortality, incidence of rejection and probability of relapse do not differ between the 117 SI+ and the 118 SI- patients at a median follow-up time of 2.5 years (minimum 0.5 years). LFS at 30 months is 56% (SE 5%) for the SI+ and 51% (SE 6%) for the SI- group (p = 0.65). LFS is better for younger patients (9/l) (p <0.05). It is worst for male recipients of a female marrow (p <0.05). The incidence of graft-versus-host disease grade ≥II was higher in the SI+ group, though not significantly. We conclude that routine splenic irradiation prior to BMT for patients with CML is of no benefit and should not be used as a routine procedure.
AB - A total of 239 patients with chronic myeloid leukaemia (CML) in chronic phase awaiting bone marrow transplantation (BMT) from an HLA-identical sibling donor were randomized to receive, as part of their conditioning, splenic irradiation (SI+) or no splenic irradiation (SI-). There was no difference between the SI+ and SI- groups regarding the distribution of age, sex, donor/recipient sex combination and blood counts at diagnosis and at BMT. Survival, leukaemia-free survival (LFS), incidence of transplant-related mortality, incidence of rejection and probability of relapse do not differ between the 117 SI+ and the 118 SI- patients at a median follow-up time of 2.5 years (minimum 0.5 years). LFS at 30 months is 56% (SE 5%) for the SI+ and 51% (SE 6%) for the SI- group (p = 0.65). LFS is better for younger patients (9/l) (p <0.05). It is worst for male recipients of a female marrow (p <0.05). The incidence of graft-versus-host disease grade ≥II was higher in the SI+ group, though not significantly. We conclude that routine splenic irradiation prior to BMT for patients with CML is of no benefit and should not be used as a routine procedure.
UR - http://www.scopus.com/inward/record.url?scp=0026761895&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026761895&partnerID=8YFLogxK
M3 - Article
C2 - 1525604
AN - SCOPUS:0026761895
VL - 10
SP - 147
EP - 152
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 2
ER -